CLS signs agreement with IGT for development and commercialization of product for MR generated temperature monitoring
Clinical Laserthermia Systems AB (publ) and Image Guided Therapy SA (IGT) have signed an agreement, in line with the ”term sheet” previously communicated. The purpose of the agreement is to develop and commercialize a software product offering doctors MR-generated, optimal conditions for viewing, measuring and controlling tissue temperatures during treatment with laser ablation and CLS’ immune stimulating imILT® procedure.
The objective is to make the product compatible with MR systems from all leading vendors. With this new product offering CLS will strengthen its position in establishing the TRANBERG® product portfolio for image guided laser ablation and imILT® treatments within the market for interventional MR procedures.
- Our main goal is to offer the doctors, choosing to use the products of CLS, an improved workflow where they in the best way possible can monitor the treatment procedure. With this new software we will offer the hospital a more complete solution, said Lars-Erik Eriksson, CEO at CLS. In brief, the collaboration means that IGT will provide the core technology for the development of the new product, while CLS will bring the know-how of thermal therapies and the regulatory process that is required for EC approval in Europe and FDA clearance in the U.S. The new product will will be registered in CLS’ quality assurance system. CLS and IGT each covers its own costs within the project, said Lars-Erik Eriksson.
- We are aiming at having the new software product approved and ready to launch during the second half of 2019. Already today we have hospitals waiting to test the product, said Dan Mogren, CCO at CLS. The commercial part of the agreement includes joint sales and marketing of the product and with an exclusive right for CLS to sell the software together with our products for soft tissue ablation and imILT® treatments, said Dan Mogren.
IGT is a French medtech company that, utilising research work from the university in Bordeaux, has developed products in the field of MR guided, minimally invasive cancer treatments. IGT has also been involved with two main developments: MR guidance for RF ablation procedures and MR guided focused ultrasound ablation devices (MRgFUS). More about Image Guided Therapy
About the CLS TRANBERG®|Thermal Therapy System
CLS developed the system for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desk-top mobile laser unit, new innovative non-cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories. CLS utilizes unique, non-cooled, diffusing laser fiber technology to optimize heat distribution in tissue while eliminating the need for external cooling. The system also includes features designed to improve workflow and reduce procedure times.
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Ph: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se